Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2024-08-15
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, multicenter real-world study, which aims to investigate
the efficacy and safety of Jinfukang oral liquid combined with chemotherapy as first-line
treatment regimen for patients with driver-negative advanced NSCLC. 328 patients with
unresectable stage IIIB-IV NSCLC and Qi-Yin deficiency will be divided into experimental
(n=164) and control groups (n=164) according to the stratified blocked randomization.
Phase:
Phase 4
Details
Lead Sponsor:
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.